Abstract:
Article summarizes results of important clinical studies targeting on potential benefits of continuous subcutaneous
insulin infusion (CSII) by means of an insulin pump in people with type 2 diabetes. The problems are comprised into four chapters: (1) Historical introduction; (2) Effectiveness of CSII in type 1 diabetes; (3) Influence of CSII on HbA1c and global metabolic indices in type 2 diabetes; (4) Influence of temporary CSII on beta-cell recovery in recent type 2 diabetes. Conclusion: CSII appears to be an effective part of type 2 diabetes treatment aiming to early recovery of beta cell function (if introduced without delay in a recent diabetes) and to long-lasting improvement of metabolic indices (if introduced any time of diabetes development). Adequate education of pump treated persons and their family members is necessary.